BACKGROUND: Accurate, reproducible, and sensitive measurements of endogenous estrogen exposure and individual patterns of estrogen metabolism are needed for etiologic studies of breast cancer. We have developed a high-performance liquid chromatography-tandem mass spectrometry method to quantitate simultaneously 15 urinary estrogens and estrogen metabolites (EM): estrone; estradiol; 3 catechol estrogens; 5 estrogens in the 16alpha pathway, including estriol; and 5 methoxy estrogens. METHODS: Overnight urines were obtained from 45 participants. For the reproducibility study, two blinded, randomized aliquots from 5 follicular and 5 luteal premenopausal women, 5 naturally postmenopausal women, and 5 men were assayed in each of four batches. Assay coefficients of variation and intraclass correlation coefficients were calculated with ANOVA models. Data from the additional 25 participants were added to compare EM levels by menstrual/sex group and assess interindividual variability. RESULTS: For each EM, overall coefficients of variation were < or = 10%. Intraclass correlation coefficients for each menstrual/sex group were generally > or = 98%. Although geometric mean EM concentrations differed among the four groups, rankings were similar, with estriol, 2-hydroxyestrone, estrone, estradiol, and 16-ketoestradiol accounting for 60% to 75% of total urinary EM. Within each group, interindividual differences in absolute concentrations were consistently high; the range was 10- to 100-fold for nearly all EM. CONCLUSION: Our high-performance liquid chromatography-tandem mass spectrometry method for measuring 15 urinary EM is highly reproducible, and the range of EM concentrations in each menstrual/sex group is quite large relative to assay variability. Whether these patterns persist in blood and target tissues awaits further development and application of this method.
RCT Entities:
BACKGROUND: Accurate, reproducible, and sensitive measurements of endogenous estrogen exposure and individual patterns of estrogen metabolism are needed for etiologic studies of breast cancer. We have developed a high-performance liquid chromatography-tandem mass spectrometry method to quantitate simultaneously 15 urinary estrogens and estrogen metabolites (EM): estrone; estradiol; 3 catechol estrogens; 5 estrogens in the 16alpha pathway, including estriol; and 5 methoxy estrogens. METHODS: Overnight urines were obtained from 45 participants. For the reproducibility study, two blinded, randomized aliquots from 5 follicular and 5 luteal premenopausal women, 5 naturally postmenopausal women, and 5 men were assayed in each of four batches. Assay coefficients of variation and intraclass correlation coefficients were calculated with ANOVA models. Data from the additional 25 participants were added to compare EM levels by menstrual/sex group and assess interindividual variability. RESULTS: For each EM, overall coefficients of variation were < or = 10%. Intraclass correlation coefficients for each menstrual/sex group were generally > or = 98%. Although geometric mean EM concentrations differed among the four groups, rankings were similar, with estriol, 2-hydroxyestrone, estrone, estradiol, and 16-ketoestradiol accounting for 60% to 75% of total urinary EM. Within each group, interindividual differences in absolute concentrations were consistently high; the range was 10- to 100-fold for nearly all EM. CONCLUSION: Our high-performance liquid chromatography-tandem mass spectrometry method for measuring 15 urinary EM is highly reproducible, and the range of EM concentrations in each menstrual/sex group is quite large relative to assay variability. Whether these patterns persist in blood and target tissues awaits further development and application of this method.
Authors: R T Falk; M H Gail; T R Fears; S C Rossi; F Stanczyk; H Adlercreutz; P Kiura; K Wahala; J L Donaldson; J B Vaught; C M Fillmore; R N Hoover; R G Ziegler Journal: Cancer Epidemiol Biomarkers Prev Date: 1999-06 Impact factor: 4.254
Authors: Jennifer D Brooks; Wendy E Ward; Jacqueline E Lewis; John Hilditch; Leslie Nickell; Evelyn Wong; Lilian U Thompson Journal: Am J Clin Nutr Date: 2004-02 Impact factor: 7.045
Authors: W Yue; R J Santen; J-P Wang; Y Li; M F Verderame; W P Bocchinfuso; K S Korach; P Devanesan; R Todorovic; E G Rogan; E L Cavalieri Journal: J Steroid Biochem Mol Biol Date: 2003-09 Impact factor: 4.292
Authors: T J Key; D Y Wang; J B Brown; C Hermon; D S Allen; J W Moore; R D Bulbrook; I S Fentiman; M C Pike Journal: Br J Cancer Date: 1996-06 Impact factor: 7.640
Authors: N C Onland-Moret; R Kaaks; P A H van Noord; S Rinaldi; T Key; D E Grobbee; P H M Peeters Journal: Br J Cancer Date: 2003-05-06 Impact factor: 7.640
Authors: Sally B Coburn; Frank Z Stanczyk; Roni T Falk; Katherine A McGlynn; Louise A Brinton; Joshua Sampson; Gary Bradwin; Xia Xu; Britton Trabert Journal: Cancer Causes Control Date: 2018-12-01 Impact factor: 2.506
Authors: Alissa Renne; Lindi Luo; Jonathan Jarow; William W Wright; Terry R Brown; Haolin Chen; Barry R Zirkin; Marlin D Friesen Journal: J Androl Date: 2011-10-20
Authors: Renée T Fortner; Hannah Oh; Sarah E Daugherty; Xia Xu; Susan E Hankinson; Regina G Ziegler; A Heather Eliassen Journal: Horm Cancer Date: 2014-01-10 Impact factor: 3.869
Authors: Julia S Sisti; Susan E Hankinson; Neil E Caporaso; Fangyi Gu; Rulla M Tamimi; Bernard Rosner; Xia Xu; Regina Ziegler; A Heather Eliassen Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-06-10 Impact factor: 4.254
Authors: Barbara J Fuhrman; Louise A Brinton; Ruth M Pfeiffer; Xia Xu; Timothy D Veenstra; Barbara E Teter; Celia Byrne; Cher M Dallal; Maddalena Barba; Paola C Muti; Gretchen L Gierach Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-06-26 Impact factor: 4.254
Authors: Steven C Moore; Charles E Matthews; Xiao Ou Shu; Kai Yu; Mitchell H Gail; Xia Xu; Bu-Tian Ji; Wong-Ho Chow; Qiuyin Cai; Honglan Li; Gong Yang; David Ruggieri; Jennifer Boyd-Morin; Nathaniel Rothman; Robert N Hoover; Yu-Tang Gao; Wei Zheng; Regina G Ziegler Journal: J Natl Cancer Inst Date: 2016-05-18 Impact factor: 13.506